Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3 ½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Lymphoma | Pharmaceuticals